akt-i-1

AKT-I-1 is a selective and reversible inhibitor of Akt1.

Akt-I-1,2 is a selective inhibitor of Akt1 and Akt2.

Angiotensin I/II (1-5) is a peptide (ASP-ARG-VAL-TYR-ILE) that contains the amino acids 1-5 and is converted from Angiotensin I/II.

IGF-I 30-41 acetate(82177-09-1 free base) (Insulin-like Growth Factor I (30-41) acetate) is amino acids 30 to 41 fragment of Insulin-like Growth Factor I (IGF-I).

Angiotensin I/II (1-6) is a peptide (ASP-ARG-VAL-TYR-ILE-HIS) that contains the amino acids 1-6 and is converted from Angiotensin I/II peptide.

1-Hydroxybaccatin I possesses significant antinociceptive activity against p- benzoquinone-induced abdominal contractions.

Gastrin I (1-14), human, is the 1-14 peptide fragment of human gastrin I, an endogenous gastrointestinal peptide hormone, and is the primary hormonal regulator of gastric acid secretion.

Gastrin I (1-14), human TFA, is the 1-14 fragment of the human gastrin I peptide.

AKT-IN-1 (AZD-26) is an allosteric AKT inhibitor (IC50: 1.04 μM).

Topo I-IN-1 (Compound 14d) is a potent Topo I inhibitor that exhibits antitumor activity, DNA intercalative capability, and can induce cell apoptosis.

Proteasome β2c i-IN-1 (compound 37) is a selective inhibitor of the β2c and β2i subunits of the human proteasome [1].

Pol I-IN-1 is a potent inhibitor of RNA polymerase I (Pol I), specifically targeting the large catalytic subunit RPA194, with an inhibition concentration (IC50) of 0.21 μM [1].

Akt NF-κB MAPK-IN-1 (compound 2m) is a potent, orally active inhibitor of NO with an IC50 of 7.70 μM and low toxicity, exhibiting anti-inflammatory effects by blocking the Akt NF-κB and MAPK signaling pathways [1].

Akt ROCK-IN-1 (B12) is a dual inhibitor of Akt and ROCK with IC50 values of 0.023 nM and 1.47 nM, respectively, and demonstrates antitumor efficacy against neuroblastoma [1].

PI3K/Akt/CREB Activator 1 is a potent, orally active compound that acts as an activator for the PI3K/Akt/CREB pathway. It enhances neuronal proliferation, induces differentiation of Neuro-2a cells into neuron-like morphology, and accelerates axon-dendrite polarization in primary hippocampal neurons by upregulating brain-derived neurotrophic factor. This compound is utilized in vascular dementia (VaD) research.

This is a peptide inhibitor of collagen fibrillar matrix assembly.

hCA I-IN-1 is a human carbonic anhydrase I (hCA I) inhibitor that acts on hCA I (Ki: 38.3 nM), hCA II (Ki: 716.4 nM), hCAIX (Ki: 940.1 nM) and hCAXII (Ki: 192.8 nM).

AChE hCA I II-IN-1 (Compound 6) is a potent AChE Hca inhibitor with IC50 values of 22.21, 60.79, and 66.64 nM for AChE, Hca Ⅰ, and Hca Ⅱ. AChE hCA I II-IN-1 can be used in glaucoma, Alzheimer's disease, and diabetes research[1].

Glyoxalase I inhibitor 1 is a potent inhibitor of glyoxalase I (GLO1) (IC50: 26 nM).

1-Hydroxylbaccatin I is a useful organic compound for research related to life sciences and the catalog number is T131467.

IGF-I (30-41) (TFA) is amino acids 30 to 41 fragment of Insulin-like Growth Factor I (IGF-I).

Hras-1Y i-motif Probe-1 is a probe of the hras-1Y i-motif which selectively and directly interacts with it.

IRAK-1-4 Inhibitor I is a dual inhibitor targeting IRAK1 and IRAK4.

Akt mTOR-IN-1 (Compound 8r) is an inhibitor of the AKT mTOR signaling pathway, exhibiting an IC50 of 0.8 µM and possessing anticancer activity. This compound decreases the expression of Caspase 3 while enhancing the expression of the autophagic protein Cyclin B1, thereby inducing autophagy and apoptosis. Akt mTOR-IN-1 is applicable for research in the field of non-small cell lung cancer (NSCLC).

Angiotensin I II (1-6) TFA is a chemical compound comprising amino acids 1-6, derived from the Angiotensin I II peptide. This peptide is formed by the cleavage of angiotensinogen by renin, with Angiotensin I subsequently hydrolyzed by angiotensin-converting enzyme (ACE) to produce biologically active Angiotensin II. Angiotensin II has been extensively studied for its potential applications in the treatment of Hypertension, Renin Angiotensin System, and Idiopathic Membranous Nephropathy[1][2][3].

PI3K/AKT-IN-1 is a potent, dual PI3K/AKT inhibitor that acts on PI3Kγ (IC50: 6.99 μM), PI3Kδ (IC50: 4.01 μM) and AKT (IC50: 3.36 μM). PI3K/AKT-IN-1 induces caspase 3-dependent apoptosis by inhibiting the PI3K/AKT pathway. caspase 3-dependent apoptosis and exhibited anticancer effects.

EGFR Akt-IN-1 (compound 17) serves as an effective inhibitor of EGFR Akt, exhibiting IC50 values of 12.89 μM and 10.88 μM in A549 cells, respectively. This compound induces cell cycle arrest at the S phase.

Angiotensin I, asn(1)-val(5)-gly(9)- is isolated from the plasma of American eel, Anquilla rostrata.

APN AKT-IN-1 is a potent dual inhibitor of aminopeptidase N (APN) and protein kinase B (AKT), with IC50 values of 0.21 μM for APN and 0.27 μM for AKT inhibition. The compound effectively suppresses the phosphorylation of glycogen synthase kinase 3 beta (GSK3β), an intracellular substrate of AKT [1].

Topo I COX-2-IN-1 (1H-30) is a potent Topo I COX-2 inhibitor with IC50 values of 0.24 μM for COX-2 and 4.42 μM for Topo I. It induces apoptosis and inhibits cancer cell migration, demonstrating anti-cancer activity.

Akt NF-κB JNK-IN-1 (Compound 2i) is an inhibitor of the Akt, NF-κB, and JNK signaling pathways, demonstrating inhibition of nitric oxide production (IC50: 3.15 μM) and exhibiting anti-inflammatory effects.

VEGFR-2 AKT-IN-1 (compound 17) is a dual inhibitor of VEGFR-2 and AKT with IC50 values of 0.164 μM and 0.452 μM, respectively. It exhibits antitumor activity.

Polyphyllin D induces apoptosis via the mitochondrial apoptotic pathway as evidenced by decreased Bcl-2 expression levels, disruption of MMP and increased Bax, cytochrome C, and cleaved-caspase-3 levels. Polyphyllin D has an anti-angiogenic effect. Polyphyllin D has toxicity in human RBCs as well as its underlying mechanism for the hemolysis and eryptosis erythroptosis. Polyphyllin D has strong anticancer activity, can overcome drug resistance in R-HepG2 cells and elicit programmed cell death via mitochondrial dysfunction.

AMG 511 is a potent and orally available pan inhibitor of class I PI3Ks (Kis of 4 nM, 6 nM, 2 nM, and 1 nM for PI3Kα, β, δ, and γ, respectively), exhibiting anti-tumor activity in a mouse glioblastoma xenograft model[1]. AMG 511 significantly suppresses PI3K signaling as indicated by a decrease in p-Akt (Ser473).

1. Artemitin (Erianthin) has anti-inflammatory activity. 2. Artemitin (Erianthin) protects endothelial function by acting as antioxidant and antiapoptotic agent and through the activation of ERK1 2 and Akt. 3. Intravenous injection of Artemitin (Erianthin)(.75 mg kg) significantly reduces the hypertensive response to angiotensin I while increases the average length of bradykinin-induced hypotension.